Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
NCT06246799 on ClinicalTrials.gov · last registry update 2026-03-10
Recruiting now, toward 256 participants. Due to report 30 April 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: number of subjects achieving HbA1c <6.5% at 6 months (Efficacy). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor type
- Other
- Enrollment
- 256
- Started
- 2024-11-07
- Primary completion
- 2029-04-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
number of subjects achieving HbA1c <6.5% at 6 months (Efficacy)
Conditions studied
Type 2 Diabetes (Adult Onset)
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.